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Available online 6 August 2016Homozygous loss-of-function mutations in the gene coding for the homeobox transcription factor PDX1 leads to
pancreatic agenesis, whereas certain heterozygous point mutations are associated with Maturity-Onset Diabetes
of the Young 4 (MODY4) and Type 2 Diabetes Mellitus (T2DM). To understand the pathomechanism of MODY4
and T2DM, we have generated iPSCs from a woman with a C18R heterozygous mutation in the transactivation
domain of PDX1. The resulting PDX1 C18R iPSCs generated by episomal reprogramming are integration-free,
have a normal karyotype and are pluripotent in vitro and in vivo. Taken together, this iPSC line will be useful to
study diabetes pathomechanisms.
© 2016 Helmholtz Zentrum München GmbH. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).(Resource tableA
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The Tübingen Family Study for T2DM (TÜF study, N = 2500) was
screened for known rare mutations in the MODY4 gene PDX1. By mass
spectrometry-based genotyping, one heterozygous PDX1 C18R carrier
could be identiﬁed and recruited for full-thickness skin biopsy. From
the biopsymaterial, the epidermal layer was separated from the dermis
by dispase digestion and ﬁbroblasts were isolated from the dermis by
trypsin digestion using an established protocol (see the Materials andn access article under the CC BY-NC-ND license
293X. Wang et al. / Stem Cell Research 17 (2016) 292–295methods section). The PDX1 C18R ﬁbroblasts were expanded using
commercially available growth media and deep-frozen in liquid nitro-
gen. From this collection of dermal ﬁbroblasts, samples were tested
for the presence of viruses pathogenic to humans (HBV, HCV, HIV) asFig. 1. Generation of PDX1 C18R iPSCs. (A) An overview of the PDX1 protein structure. (B) Sch
Reprogramming protocol of skin ﬁbroblasts into integration-free iPSCs using episomal vecto
shows heterozygous T N C mutation in PDX1. (F) Semi-quantitative PCR conﬁrms that episom
H9 ESCs and two independent iPSC clones (#1 and #2) were used as negative controls, wherewell as for the presence of mycoplasma. All cultures were found to be
negative for all of these potential contaminants. PDX1 C18R primary ﬁ-
broblasts were reprogrammed into iPSCs using nucleofection with
three episomal plasmids encoding human OCT4, SOX2, NANOG, LIN28,eme shows the reprogramming factors for the generation of the PDX1 C18R iPSC line. (C)
rs. (D) Normal karyotype (46, XX) of one PDX1 C18R iPSC clone. (E) Sequencing result
al vectors did not integrate into the genomic DNA of the selected PDX1 C18R iPSC clone.
as transfected ﬁbroblast at day 6 were used as positive controls.
294 X. Wang et al. / Stem Cell Research 17 (2016) 292–295KLF4, and L-MYC (Fig. 1B). The reprogramming protocol (transfection,
reprogramming and expansion) is shown in Fig. 1C. 3 weeks after trans-
fection, many colonies with human embryonic stem cell (hESC)-like
morphology appeared that were hand picked by day 21, expanded
and frozen down as individual iPSC lines. The analysis of one of these
iPSC lines conﬁrmed that PDX1 C18R ﬁbroblasts were successfully
reprogrammed into iPSCs with a normal karyotype (Fig. 1D) and con-
taining the T N C mutation causing a C18R amino acid exchange in the
transactivation domain (Fig. 1A, E). Integration of the exogenous
transgenes in the genome of iPSCs was excluded by semi-quantitative
PCR (Fig. 1F). To conﬁrm that this iPSC line was pluripotent, we per-
formed immunoﬂuorescence staining for the pluripotency transcription
factors OCT4 and SOX2, as well as for the hESC surface markers SSEA-3,
SSEA-4 and TRA-1-81, which were all expressed in the PDX1 C18R iPSC
line (Fig. 2A). To further demonstrate pluripotency of the selected iPSC
line we injected 2 × 106 cells subcutaneously into NOD/SCID mice to
generate teratomas. The histological analysis of the induced teratomas
revealed that all tissues from all three germ layers were differentiated
conﬁrming pluripotency in this in vivo assay (Fig. 2B). Taken together,
we have successfully reprogrammed PDX1 C18R dermal ﬁbroblasts
into pluripotent iPSCs that can be used to study a point mutation in
the transactivation domain of PDX1 to study the development of
diabetes.Fig. 2. PDX1 C18R iPSCs are pluripotent and differentiate into all germ layers in vivo. (A) PDX1
several pluripotency markers. Scale bar indicates 50 μm. (B) Hematoxylin/eosin staining of
derivatives are clearly detectable in vivo. Scale bar indicates 100 μm.Materials and methods
Ethics statement
The study adhered to the Declaration of Helsinki. All participants
gave informed written consent, and the study protocols were approved
by the local ethics board (Ethics Committee of the Eberhard Karls Uni-
versity Tübingen).
Study participants
The ongoing TÜF study currently includes N3000 non-related individ-
uals at risk for type-2 diabetesmellitus (T2DM), i.e., healthy subjects with
a family history of T2DM, a bodymass index ≥27 kg/m2, impaired fasting
glycaemia, and/or previous gestational diabetes (Stefan et al., 2005). From
all TÜF participants, themedical history, smoking status, and alcohol con-
sumption habits were queried and documented. Furthermore, all partici-
pants underwent physical examination, routine blood tests, bioelectric
impedance measurement, and 5-point oral glucose tolerance tests
(OGTTs) with insulin and glucose measurements. The current study pop-
ulation comprised 2500 individuals who spent DNA for genotyping, were
not on anymedication known to inﬂuence glucose tolerance, insulin sen-
sitivity, or insulin secretion, and who had complete OGTT data sets.C18R iPSCs display typical morphological ESC-like characteristics and uniformly express
tissue sections of teratomas generated from the PDX1 C18R iPSC clone. All germ layer-
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fromSequenom (Hamburg, Germany) and themanufacturer's iPLEX soft-
ware, the 2500 subjects were screened for known rare mutations in ma-
turity onset of diabetes (MODY) genes that were described in the
literature to co-segregate with MODY phenotypes in families. We identi-
ﬁed seven individuals with heterozygous mutations in PDX1 (MODY4)
(McKinnon and Docherty, 2001). From these cases, one glucose-tolerant
female PDX1 Cys18Arg (C18R) carrier (aged 33 years; BMI 20.6 kg/m2)
with history of diabetes could be recruited for full-thickness skin biopsy.
Skin biopsy, isolation and testing of dermal ﬁbroblasts
A full-thickness skin specimen was taken by punch biopsy from the
upper arm in the deltoid muscle region. After removal of adipose tissue
remnants and visible blood vessels, the sample was digested overnight
at 4 °C with 10 U/ml dispase II (Roche Diagnostics, Mannheim, Germa-
ny) in 50 mM Hepes pH 7.4, 150 mM NaCl. Thereafter, the digest was
heated for 30 min at 37 °C under continuous shaking (1200 rpm).
Using forceps, the dermis was separated from the epidermal layer, and
ﬁbroblasts were isolated from the dermis by digestion with 0.2% colla-
genase CLS I (Biochrom, Berlin, Germany) in DMEM, 10% BSA for
45 min at 37 °C under continuous shaking (1200 rpm). For puriﬁcation
of theﬁbroblasts, the digestwasﬁltered through a 70 μmmesh and cen-
trifuged. The pelleted cells were resuspended, grown for three days in
DMEM, 10% FCS, and subsequently further expanded in Medium 106
supplemented with low serum growth supplement (Invitrogen, Ther-
mo Fisher Scientiﬁc, Waltham, MA, USA). Samples of dermal ﬁbroblasts
were tested for the presence of viruses pathogenic to humans, i.e., HBV,
HCV, and HIV, with Genesig PCR-based detection kits from
Primerdesign Ltd. (Chandler's Ford, UK) and for the presence of myco-
plasma with a PCR test kit from PanReac AppliChem (Darmstadt, Ger-
many) and, in parallel, by DNA staining with DAPI. All cultures were
found to be negative for the tested contaminants.
iPSC generation
Primary ﬁbroblasts frompatientwere reprogrammed into pluripotent
stem cells by using a non-integrating Episomal iPSC Reprogramming Kit
(Invitrogen, Cat. no. A14703). This kit contains mixture of three vectors
which has the oriP/EBNA-1 (Epstein-Barr unclear antigen-1) backbone
that delivers six reprogramming factors: OCT4, SOX2, NANOG, LIN28,
KLF4, and L-MYC (Yu et al., 2011). Humanﬁbroblasts at 75–90% conﬂuent
were transfected using the Amaxa 4D-Nucleofector transfection system
and a nucleofector kit for human dermal ﬁbroblast (Lonza, Cat. no. VPD-
1001), plated onto geltrex-coated culture dishes, incubated in supple-
mented ﬁbroblast medium. This medium contained knockout DMEM/F-
12 (Life technologies), 10% FBS of ESC-qualiﬁed (Life technologies), 1%
MEM non-essential amino acids (Life technologies), 10 μM HA-100
(Santa Cruz) and 4 ng/ml bFGF (Life technologies). At 24 h after transfec-
tion, the medium were exchanged with N2B27 medium supplemented
with 0.5 μM PD0325901 (Stemgent), 3 μM CHIR99021 (Stemgent),
0.5 μM A-83-01 (Stemgent), 10 μM HA-100 (Santa Cruz), 10 ng/ml hLIF
(Life technologies) and 100 ng/ml bFGF. The basic N2B27 medium
contained DMEM/F12withHEPES (Life technologies), 1×N2 supplement
(Life technologies), 1×B27 supplement (Life technologies), 1%MEMnon-
essential amino acids, 1× Glutamax (Life technologies) and 1× β-
Mercaptoethanol (Life technologies). On day 15 after transfection, the
medium was exchanged with Essential 8 medium and monitored for
the emergence of iPSC colonies. Around 3weeks after transfection, undif-
ferentiated iPS colonies were picked and transferred onto fresh geltrex-
coated culture dishes for expansion.
iPSC characterization
DNA was extracted from iPSCs by using standard procedure. Markers
for the episomal backbone were ampliﬁed by semi-quantitative PCR toexclude transgene integration. Primers are as follows: oriP forward:
TTCCACGAGGCTAGTGAACC. oriP reverse: TCGGGGGTGTTAGAGACAAC;
EBNA-1 forward: ATCGTCAAAGCTGCACACAG. EBNA-1 reverse:
CCCAGGAGTCCCAGTAGTCA. For karyotype analysis, we used the cells
growing in logarithmic phase. They were fed with fresh medium the
night before adding colcemid for 2 h. Cells were then trypsinized, treated
with hypotonic solution (0.075 M KCl) for 20 min and ﬁxed with
methanol:acetic acid (3:1). Metaphases were spread on microscope
slides, and chromosomes were classiﬁed according to the International
System forHumanCytogenicNomenclature using the standardGbanding
technique. At least, 20 metaphases were counted per cell line, and the
ﬁnal karyotype was stated if it was present in N85% of them. For terato-
mas, 2 × 106 iPSCs were injected into the right hind leg of immunocom-
promised NOD/SCID mice. Tumors were excised after 8 weeks, ﬁxed,
embedded in parafﬁn, sectioned and stained with hematoxylin/eosin
(Takahashi et al., 2007).
Mutation analysis
Genomic DNA was isolated from PDX1 C18R and control iPSCs using
standard procedure. PCR ampliﬁcation with a set of primers ﬂanking the
mutation site was performed in those two samples. PCR products were se-
quencedusing the reverseprimerbySanger sequencingonanABI3130ge-
netic analyzer (Applied Biosystems). Primers are as follows: PDX1 forward:
GGAGTGTGCAGCAAACTCAG, PDX1 reverse: ACGCGTGAGCTTTGGTAGAC.
Immunoﬂuorescence imaging
Cells were ﬁxed with 4% paraformaldehyde for 30 min and then
permeabilized in PBS containing 0.2% Triton X-100. Cells were blocked
with PBS containing 3% BSA, and incubated with primary antibodies
overnight at 4 °C. Then secondary antibodies were incubated for 1 h at
room temperature after washing with PBS. Images were acquired on a
laser scanning microscope. The following antibodies and dilutions were
used: goat anti-OCT3/4 (1:500, Santa Cruz), goat anti-SOX2 (1:500,
Santa Cruz), rat anti-SSEA3 (1:50, Invitrogen), mouse anti-SSEA4
(1:500, cell signaling) and mouse anti-TRA-1-81 (1:50, Millipore).
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